Medicenna Therapeutics Corp.

09:53 AM EST - Medicenna Therapeutics Corp. : Announced that Dr. Dina Randazzo of Duke University will present updates related to the recently completed Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma at the 2019 Annual Meeting of the American Society of Clinical Oncology to be held from May 31 to June 4, in Chicago. Medicenna Therapeutics Corp. shares T.MDNA are trading down $0.02 at $0.66.